查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1623069

抗血友病因子药物的全球市场规模:各产品，各用途，各地区，范围及预测

Global Antihemophilic Factor Drug Market Size By Product (250 IU, 500 IU, 1000 IU, 1500 IU), By Application (Adult, Pediatric), By Geographic Scope and Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

抗血友病因子药物的市场规模及预测

抗血友病因子药物的市场规模近年来一直以显着的速度快速增长，预计在市场估计和预测期（2021-2028 年）内将显着增长。

抗血友病因子药物用于治疗和控制出血性疾病患者的严重出血事件。人们认识的提高和全球人口中罕见疾病的增加是医疗保健行业面临的关键问题，这推动了抗血友病因子药物市场的成长。全球抗血友病因子药物市场报告对市场进行了全面的评估。它对关键细分市场、趋势、市场推动因素、阻碍因素、竞争格局以及在市场中发挥关键作用的因素进行了全面的分析。

定义全球抗血友病因子药物市场

抗血友病因子药物用于减缓和预防血液凝血因子 VIII 水平低下（血友病 A）患者的出血发作。它也可用于手术前的止血。凝血因子 VIII 水平正常的人，由于体内存在凝血因子 VIII（又称抗血友病因子），因此在受伤、手术和凝血因子 VIII 出血后出现出血的风险会增加。该製剂暂时取代丢失的第八因子。通常情况下，蛋白质的存在有助于血液凝结和止血。这种药物通常透过静脉注射至少 5 到 10 分钟，或按照医生的指示注射。可能需要随着时间的推移缓慢地给药，这取决于剂量和患者的反应。

全球抗血友病因子药物市场概况

推动市场成长的主要因素是人口中罕见疾病病例的增加。此药用于抑制和预防血液凝血因子 VIII 水平低下（血友病 A）患者的出血发作。它也用于这些患者手术前的止血。血液凝固因子 VIII 水平正常的个体在受伤/手术后或内出血的风险会增加。本品含人体凝血因子VIII，又称抗血友病因子。本产品暂时取代缺失的第八因子（第八因子为血液中正常存在的蛋白质），有助于血液凝结和止血。民众对这些罕见疾病认识的提高以及政府参与预防和管理这些危及生命的疾病是推动抗血友病药物市场预计成长的主要因素。此外，各大製药公司对血友病新疗法研发的投入不断增加，推动着市场的快速扩张。

儘管透过对捐血者的仔细筛检、专有製造流程和大量测试来降低这种风险，但这种药物的感染风险很小，限制了抗血友病因子药物市场的成长。

目录

第1章 全球抗血友病因子药物市场简介

  • 市场概要
  • 调查范围
  • 前提条件

第2章 摘要整理

第3章 VERIFIED MARKET RESEARCH的调查手法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源一览

第4章 抗血友病因子药物的全球市场展望

  • 概要
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
  • 波特的五力分析
  • 价值链分析

第5章 抗血友病因子药物的全球市场:各产品

  • 概要
  • 250 IU
  • 500 IU
  • 1000 IU
  • 1500 IU
  • 2000 IU
  • 3000 IU
  • 4000 IU
  • 其他

第6章 抗血友病因子药物的全球市场:各用途

  • 概要
  • 成人
  • 儿童

第7章 抗血友病因子药物的全球市场:各地区

  • 概要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 全球其他地区
    • 南美
    • 中东·非洲

第8章 全球抗血友病因子药物市场竞争情形

  • 概要
  • 各公司的市场排行榜
  • 主要的开发策略

第9章 企业简介

  • Bayer
  • Shire
  • Novo Nordisk
  • Pfizer
  • Grifols
  • CSL Behring
  • Sanofi
  • Cigna
  • Octapharma
  • GC Pharma

第10章 相关报告相关报告

简介目录
Product Code: 14401

Antihemophilic Factor Drug Market Size and Forecast

Antihemophilic Factor Drug Market size is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028.

Antihemophilic factor drug is used to treat and control severe bleeding spells in patients with a bleeding problem. Increasing awareness among people and growing rare disorders among people across the globe is a significant problem for the healthcare field is the factor driving the market growth of the Antihemophilic Factor Drug Market. The Global Antihemophilic Factor Drug Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Antihemophilic Factor Drug Market Definition

Anti-hemophilia factor drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to stop bleeding. People with normal factor VIII levels are at increased risk of injury, post-surgery bleeding, and factor VIII bleeding in the body, also known as an anti-hemophilia factor. This product temporarily replaces lost factor VIII. A protein is usually present to help blood clots and stop bleeding. The medicine is usually given by intravenous injection for at least 5-10 minutes or as directed by the doctor. Depending on your dose and patient response, the drug may need to be given more slowly over time. After receiving this medicine for the first time at a hemophilia treatment center or hospital, some patients can self-administer this medicine at home. The drugs and solutions used for mixing were refrigerated. After adding the resolution to the powder, some brands of this drug may need to shake the vial for 10-15 seconds before gently rotating the vial to dissolve the powder completely. Ask your pharmacist about the correct combination of the medicines. Visually inspect for particulate matter or discoloration before using this product.

Global Antihemophilic Factor Drug Market Overview

The primary factor driving the market growth is the increasing number of rare disorder cases among people is the factor driving the market growth. This drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to stop bleeding. People at the general factor VIII level are at increased risk of injury / post-surgery and internal bleeding. This product contains Human Factor VIII, also known as an anti-hemophilia factor. This product temporarily replaces lost element VIII and a protein usually present in the blood to help blood clots and stop bleeding. Increasing awareness of such rare diseases among the population and government involvement in preventing and managing these life-threatening diseases are key factors behind the estimated growth of the antihemophilic drug market. In addition, increased investment by leading pharmaceutical companies in the research and development of new treatments for hemophilia is driving market expansion at an alarming rate.

Careful screening of blood donors, a unique manufacturing process, and many tests have been used to reduce this risk, but the risk of infection with this drug is minimal, limiting the market growth of the Antihemophilic factor Drug Market.

Global Antihemophilic Factor Drug Market: Segmentation Analysis

The Global Antihemophilic Factor Drug Market is segmented on the basis of Product, Application, and Geography.

Antihemophilic Factor Drug Market by Product

  • 250 IU
  • 500 IU
  • 1000 IU
  • 1500 IU
  • 2000 IU
  • 3000 IU
  • 4000 IU
  • Other potencies

Based on Product, the market is segmented into 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU, 3000 IU, 4000 IU and Other potencies.

Antihemophilic Factor Drug Market by Application

  • Adult
  • Pediatric

Based on the Application, the Adult segment holds a large number of shares in the market because the low risk for hypersensitivity reactions increases cases of disorders in adult ages peoples, which is the factor that boosts the market growth of the Antihemophilic factor Drug Market.

Antihemophilic Factor Drug Market by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

Based on Geography, the North American region holds a large number of shares in the market because of the increasing number of cases in the region. The existence of key players in the region is the factor that propels the market growth of the Antihemophilic factor Drug Market.

Key Players

The "Global Antihemophilic Factor Drug Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are

Bayer, Shire, Novo Nordisk, Pfizer, Grifols, CSL Behring, Sanofi, Cigna, Octapharma, and GC Pharma.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET, BY PRODUCT

  • 5.1 Overview
  • 5.2 250 IU
  • 5.3 500 IU
  • 5.4 1000 IU
  • 5.5 1500 IU
  • 5.6 2000 IU
  • 5.7 3000 IU
  • 5.8 4000 IU
  • 5.9 Other potencies

6 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Adult
  • 6.3 Pediatric

7 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East and Africa

8 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Bayer
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Shire
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Novo Nordisk
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Pfizer
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Grifols
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 CSL Behring
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Development
  • 9.7 Sanofi
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Cigna
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Octapharma
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Development
  • 9.10 GC Pharma
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Development

10 Related Reports